Using Fisher Information Matrix to predict uncertainty in covariate effects and power to detect their relevance in Non-Linear Mixed Effect Models in pharmacometrics

This work focuses on design of experiments for Pharmacokinetic (PK) and Pharmacodynamic (PD) studies. Non-Linear Mixed Effects Models (NLMEM) modelling allows the identification and quantification of covariates that explain inter-individual variability (IIV). The Fisher Information Matrix (FIM), com...

Full description

Saved in:
Bibliographic Details
Published inJournal of pharmacokinetics and pharmacodynamics Vol. 52; no. 4; p. 38
Main Authors Fayette, Lucie, Brendel, Karl, Mentré, France
Format Journal Article
LanguageEnglish
Published New York Springer US 14.07.2025
Springer Nature B.V
Subjects
Online AccessGet full text
ISSN1567-567X
1573-8744
1573-8744
DOI10.1007/s10928-025-09987-2

Cover

Loading…
Abstract This work focuses on design of experiments for Pharmacokinetic (PK) and Pharmacodynamic (PD) studies. Non-Linear Mixed Effects Models (NLMEM) modelling allows the identification and quantification of covariates that explain inter-individual variability (IIV). The Fisher Information Matrix (FIM), computed by linearization, has already been used to predict uncertainty on covariate parameters and power of test to detect statistical significance. A covariate effect is deemed statistically significant if it is different from 0 according to a Wald comparison test and clinically relevant if the ratio of change it causes in the parameter is relevant according to a test inspired by the two one-sided tests (TOST) as in bioequivalence studies. FIM calculation was extended by computing its expectation on the joint distribution of the covariates, discrete and continuous. Three methods were proposed: using a provided sample of covariate vectors, simulating covariate vectors, based on provided independent distributions or on estimated copulas. Thereafter, CI of ratios, power of tests and number of subjects needed to achieve desired confidence were derived. Methods were implemented in a working version of the R package PFIM6.1 . A simulation study was conducted under various scenarios, including different sample sizes, sampling points, and IIV. Overall, uncertainty on covariate effects and power of tests were accurately predicted. The method was applied to a population PK model of the drug cabozantinib including 27 covariate relationships. Despite numerous relationships, limited representation of certain covariates, FIM correctly predicted uncertainty, and is therefore suitable for rapidly computing number of subjects needed to achieve given powers. Graphical abstract
AbstractList This work focuses on design of experiments for Pharmacokinetic (PK) and Pharmacodynamic (PD) studies. Non-Linear Mixed Effects Models (NLMEM) modelling allows the identification and quantification of covariates that explain inter-individual variability (IIV). The Fisher Information Matrix (FIM), computed by linearization, has already been used to predict uncertainty on covariate parameters and power of test to detect statistical significance. A covariate effect is deemed statistically significant if it is different from 0 according to a Wald comparison test and clinically relevant if the ratio of change it causes in the parameter is relevant according to a test inspired by the two one-sided tests (TOST) as in bioequivalence studies. FIM calculation was extended by computing its expectation on the joint distribution of the covariates, discrete and continuous. Three methods were proposed: using a provided sample of covariate vectors, simulating covariate vectors, based on provided independent distributions or on estimated copulas. Thereafter, CI of ratios, power of tests and number of subjects needed to achieve desired confidence were derived. Methods were implemented in a working version of the R package PFIM6.1. A simulation study was conducted under various scenarios, including different sample sizes, sampling points, and IIV. Overall, uncertainty on covariate effects and power of tests were accurately predicted. The method was applied to a population PK model of the drug cabozantinib including 27 covariate relationships. Despite numerous relationships, limited representation of certain covariates, FIM correctly predicted uncertainty, and is therefore suitable for rapidly computing number of subjects needed to achieve given powers.This work focuses on design of experiments for Pharmacokinetic (PK) and Pharmacodynamic (PD) studies. Non-Linear Mixed Effects Models (NLMEM) modelling allows the identification and quantification of covariates that explain inter-individual variability (IIV). The Fisher Information Matrix (FIM), computed by linearization, has already been used to predict uncertainty on covariate parameters and power of test to detect statistical significance. A covariate effect is deemed statistically significant if it is different from 0 according to a Wald comparison test and clinically relevant if the ratio of change it causes in the parameter is relevant according to a test inspired by the two one-sided tests (TOST) as in bioequivalence studies. FIM calculation was extended by computing its expectation on the joint distribution of the covariates, discrete and continuous. Three methods were proposed: using a provided sample of covariate vectors, simulating covariate vectors, based on provided independent distributions or on estimated copulas. Thereafter, CI of ratios, power of tests and number of subjects needed to achieve desired confidence were derived. Methods were implemented in a working version of the R package PFIM6.1. A simulation study was conducted under various scenarios, including different sample sizes, sampling points, and IIV. Overall, uncertainty on covariate effects and power of tests were accurately predicted. The method was applied to a population PK model of the drug cabozantinib including 27 covariate relationships. Despite numerous relationships, limited representation of certain covariates, FIM correctly predicted uncertainty, and is therefore suitable for rapidly computing number of subjects needed to achieve given powers.
This work focuses on design of experiments for Pharmacokinetic (PK) and Pharmacodynamic (PD) studies. Non-Linear Mixed Effects Models (NLMEM) modelling allows the identification and quantification of covariates that explain inter-individual variability (IIV). The Fisher Information Matrix (FIM), computed by linearization, has already been used to predict uncertainty on covariate parameters and power of test to detect statistical significance. A covariate effect is deemed statistically significant if it is different from 0 according to a Wald comparison test and clinically relevant if the ratio of change it causes in the parameter is relevant according to a test inspired by the two one-sided tests (TOST) as in bioequivalence studies. FIM calculation was extended by computing its expectation on the joint distribution of the covariates, discrete and continuous. Three methods were proposed: using a provided sample of covariate vectors, simulating covariate vectors, based on provided independent distributions or on estimated copulas. Thereafter, CI of ratios, power of tests and number of subjects needed to achieve desired confidence were derived. Methods were implemented in a working version of the R package PFIM6.1 . A simulation study was conducted under various scenarios, including different sample sizes, sampling points, and IIV. Overall, uncertainty on covariate effects and power of tests were accurately predicted. The method was applied to a population PK model of the drug cabozantinib including 27 covariate relationships. Despite numerous relationships, limited representation of certain covariates, FIM correctly predicted uncertainty, and is therefore suitable for rapidly computing number of subjects needed to achieve given powers. Graphical abstract
This work focuses on design of experiments for Pharmacokinetic (PK) and Pharmacodynamic (PD) studies. Non-Linear Mixed Effects Models (NLMEM) modelling allows the identification and quantification of covariates that explain inter-individual variability (IIV). The Fisher Information Matrix (FIM), computed by linearization, has already been used to predict uncertainty on covariate parameters and power of test to detect statistical significance. A covariate effect is deemed statistically significant if it is different from 0 according to a Wald comparison test and clinically relevant if the ratio of change it causes in the parameter is relevant according to a test inspired by the two one-sided tests (TOST) as in bioequivalence studies. FIM calculation was extended by computing its expectation on the joint distribution of the covariates, discrete and continuous. Three methods were proposed: using a provided sample of covariate vectors, simulating covariate vectors, based on provided independent distributions or on estimated copulas. Thereafter, CI of ratios, power of tests and number of subjects needed to achieve desired confidence were derived. Methods were implemented in a working version of the R package PFIM6.1. A simulation study was conducted under various scenarios, including different sample sizes, sampling points, and IIV. Overall, uncertainty on covariate effects and power of tests were accurately predicted. The method was applied to a population PK model of the drug cabozantinib including 27 covariate relationships. Despite numerous relationships, limited representation of certain covariates, FIM correctly predicted uncertainty, and is therefore suitable for rapidly computing number of subjects needed to achieve given powers.
ArticleNumber 38
Author Mentré, France
Brendel, Karl
Fayette, Lucie
Author_xml – sequence: 1
  givenname: Lucie
  orcidid: 0009-0001-0048-5998
  surname: Fayette
  fullname: Fayette, Lucie
  email: lucie.fayette@inserm.fr
  organization: Université Paris Cité et Université Sorbonne Paris Nord, IAME, Inserm, Pharmacometrics, Ipsen Innovation
– sequence: 2
  givenname: Karl
  surname: Brendel
  fullname: Brendel, Karl
  organization: Pharmacometrics, Ipsen Innovation
– sequence: 3
  givenname: France
  orcidid: 0000-0002-7045-1275
  surname: Mentré
  fullname: Mentré, France
  organization: Université Paris Cité et Université Sorbonne Paris Nord, IAME, Inserm
BackLink https://www.ncbi.nlm.nih.gov/pubmed/40659916$$D View this record in MEDLINE/PubMed
BookMark eNp9kctu1TAQhi1URC_wAiyQJTZsAmM7zmWJqrZUOgc2VGJnOc6kx1ViB9vp5X140Do9BSQWLCxb1vfNjOY_JgfOOyTkLYOPDKD-FBm0vCmAywLatqkL_oIcMVmLoqnL8mB9V3WRz49DchzjDQCrJIdX5LCESrYtq47Ir6to3TU9t3GHgV66wYdJJ-sd3eoU7D1Nns4Be2sSXZzBkLR16YFaR42_1cHqhBSHAU2KVLuezv4uF8pWjyl_0rRDG2jAEW919lfxq3fFxjrUgW7tPfb07MmnW9_jGFdi3uk8hvET5hlMfE1eDnqM-Ob5PiFX52ffT78Um28Xl6efN4URvEmFMVp2rO1Rc6g71pVmEIKxEgy0TOoWjBR9X5a61hUIBMQKoO2YaGTDy4GJE_JhX3cO_ueCManJRoPjqB36JSrBBfC8w0Zm9P0_6I1fgsvTZYqvaeTamXr3TC3dhL2ag510eFC_958BvgdM8DEGHP4gDNQastqHrHLI6ilkxbMk9lLMsLvG8Lf3f6xHu0yrRA
Cites_doi 10.1007/s10928-005-2102-z
10.1208/s12248-023-00810-9
10.1093/oso/9780199296590.003.0004
10.1002/sim.2910
10.1002/psp4.13116
10.1177/0962280219850588
10.1002/sim.4390
10.21203/rs.3.rs-3655068/v1
10.1080/10543406.2011.580484
10.1016/j.cmpb.2018.01.008
10.1007/s10928-022-09821-z
10.1007/s10928-016-9499-4
10.1002/cpt.3099
10.1080/10543406.2019.1607367
10.1081/BIP-120019267
10.1007/BF01068419
10.1002/psp4.13115
10.1016/S0169-2607(03)00073-7
10.1101/2024.02.22.24303086
10.1038/clpt.2011.149
10.1093/biomet/84.2.429
10.1002/jcph.1467
10.1016/j.cmpb.2012.05.005
10.1002/sim.10088
10.32614/CRAN.package.PFIM
10.1515/demo-2020-0022
ContentType Journal Article
Copyright The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2025 Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
2025. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2025.
Copyright_xml – notice: The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2025 Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
– notice: 2025. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
– notice: The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2025.
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7U9
H94
K9.
M7N
7X8
DOI 10.1007/s10928-025-09987-2
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Virology and AIDS Abstracts
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Algology Mycology and Protozoology Abstracts (Microbiology C)
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Virology and AIDS Abstracts
Algology Mycology and Protozoology Abstracts (Microbiology C)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic

AIDS and Cancer Research Abstracts
MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Pharmacy, Therapeutics, & Pharmacology
EISSN 1573-8744
ExternalDocumentID 40659916
10_1007_s10928_025_09987_2
Genre Journal Article
GrantInformation_xml – fundername: Association Nationale de la Recherche et de la Technologie
  funderid: http://dx.doi.org/10.13039/501100003032
GroupedDBID ---
.86
.VR
06C
06D
0R~
0VY
1N0
203
29L
29~
2J2
2JN
2JY
2KG
2KM
2LR
2~H
30V
4.4
406
408
409
40D
40E
5GY
5VS
67N
67Z
6NX
78A
7X7
8UJ
95-
95.
95~
96X
AAAVM
AABHQ
AACDK
AAHNG
AAIAL
AAJBT
AAJKR
AANZL
AAPKM
AARTL
AASML
AATNV
AATVU
AAUYE
AAWCG
AAYIU
AAYQN
AAYZH
ABAKF
ABBBX
ABBRH
ABBXA
ABDBE
ABDZT
ABECU
ABFSG
ABFTV
ABHLI
ABHQN
ABJNI
ABJOX
ABKCH
ABKTR
ABMNI
ABMQK
ABNWP
ABPLI
ABQBU
ABRTQ
ABSXP
ABTEG
ABTHY
ABTKH
ABTMW
ABWNU
ABXPI
ACAOD
ACDTI
ACGFO
ACGFS
ACHSB
ACHXU
ACIWK
ACKNC
ACMDZ
ACMLO
ACOKC
ACOMO
ACPIV
ACPRK
ACREN
ACSTC
ACZOJ
ADBBV
ADHHG
ADHIR
ADKNI
ADKPE
ADRFC
ADTPH
ADURQ
ADYFF
ADYOE
ADZKW
AEFQL
AEGAL
AEGNC
AEJHL
AEJRE
AEMSY
AENEX
AEOHA
AEPYU
AESKC
AETLH
AEVLU
AEXYK
AEZWR
AFBBN
AFDZB
AFHIU
AFLOW
AFOHR
AFQWF
AFRAH
AFWTZ
AFYQB
AFZKB
AGAYW
AGDGC
AGJBK
AGMZJ
AGQEE
AGQMX
AGRTI
AGWIL
AGWZB
AGYKE
AHAVH
AHBYD
AHKAY
AHMBA
AHPBZ
AHSBF
AHWEU
AHYZX
AIAKS
AIGIU
AIIXL
AILAN
AITGF
AIXLP
AJRNO
AJZVZ
AKMHD
ALMA_UNASSIGNED_HOLDINGS
ALWAN
AMKLP
AMTXH
AMXSW
AMYLF
AMYQR
AOCGG
ARMRJ
ATHPR
AXYYD
AYFIA
AZFZN
B-.
BA0
BENPR
BGNMA
BSONS
CS3
CSCUP
DDRTE
DL5
DNIVK
DPUIP
EBLON
EBS
EIOEI
EPAXT
ESBYG
F5P
FEDTE
FERAY
FFXSO
FIGPU
FNLPD
FRRFC
FWDCC
G-Y
G-Z
GGCAI
GGRSB
GJIRD
GNWQR
GQ7
GQ8
GXS
HF~
HG5
HG6
HMJXF
HQYDN
HRMNR
HVGLF
HZ~
I09
IJ-
IKXTQ
ITM
IWAJR
IXC
IZIGR
IZQ
I~X
I~Z
J-C
J0Z
JBSCW
JCJTX
JZLTJ
KDC
KOV
KPH
LAK
LLZTM
LSO
M4Y
MA-
N9A
NB0
NPVJJ
NQJWS
NU0
O93
O9G
O9I
O9J
OAM
P19
P2P
PF0
PT4
PT5
QOK
QOR
QOS
R89
R9I
ROL
RPX
RRX
RSV
S16
S1Z
S27
S3A
S3B
SAP
SBL
SDH
SDM
SHX
SISQX
SJYHP
SNE
SNPRN
SNX
SOHCF
SOJ
SPISZ
SRMVM
SSLCW
SSXJD
STPWE
SZN
T13
TSG
TSK
TSV
TUC
TUS
U2A
U9L
UG4
UOJIU
UTJUX
VC2
W23
W48
WJK
WK8
YLTOR
Z45
ZMTXR
ZOVNA
-Y2
.GJ
1SB
2.D
2P1
2VQ
3SX
53G
5QI
88E
8AO
8FI
8FJ
AANXM
AARHV
AAYTO
AAYXX
ABQSL
ABULA
ABUWG
ACBXY
ADHKG
ADPHR
ADYPR
AEBTG
AEFIE
AEKMD
AFEXP
AFGCZ
AFKRA
AGGDS
AGQPQ
AI.
AJBLW
BDATZ
BPHCQ
BVXVI
CAG
CCPQU
CITATION
COF
EBD
EJD
EMOBN
EN4
FINBP
FSGXE
FYUFA
H13
HMCUK
IHE
M1P
MK0
N2Q
NDZJH
O9-
OVD
PHGZM
PHGZT
PJZUB
PPXIY
PQQKQ
PROAC
PSQYO
Q2X
RNI
RZC
RZE
RZK
S26
S28
SCLPG
SV3
T16
TEORI
UKHRP
UZXMN
VFIZW
VH1
CGR
CUY
CVF
ECM
EIF
NPM
7U9
H94
K9.
M7N
7X8
ALIPV
ID FETCH-LOGICAL-c328t-cca5b19dea207b1b4cf331140c0915a90c53dd44a7a603e0ee6009b1385824f13
IEDL.DBID U2A
ISSN 1567-567X
1573-8744
IngestDate Tue Jul 15 17:30:30 EDT 2025
Sun Aug 17 03:40:54 EDT 2025
Sat Aug 16 01:30:53 EDT 2025
Thu Aug 21 00:34:54 EDT 2025
Sat Aug 16 01:10:40 EDT 2025
IsPeerReviewed true
IsScholarly true
Issue 4
Keywords Design
Pharmacometrics
Covariate effect
Non-Linear mixed effects models
Power of relevance
Fisher information matrix
Language English
License 2025. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c328t-cca5b19dea207b1b4cf331140c0915a90c53dd44a7a603e0ee6009b1385824f13
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ORCID 0000-0002-7045-1275
0009-0001-0048-5998
PMID 40659916
PQID 3229987600
PQPubID 55470
ParticipantIDs proquest_miscellaneous_3230216585
proquest_journals_3229987600
pubmed_primary_40659916
crossref_primary_10_1007_s10928_025_09987_2
springer_journals_10_1007_s10928_025_09987_2
PublicationCentury 2000
PublicationDate 2025-07-14
PublicationDateYYYYMMDD 2025-07-14
PublicationDate_xml – month: 07
  year: 2025
  text: 2025-07-14
  day: 14
PublicationDecade 2020
PublicationPlace New York
PublicationPlace_xml – name: New York
– name: United States
PublicationTitle Journal of pharmacokinetics and pharmacodynamics
PublicationTitleAbbrev J Pharmacokinet Pharmacodyn
PublicationTitleAlternate J Pharmacokinet Pharmacodyn
PublicationYear 2025
Publisher Springer US
Springer Nature B.V
Publisher_xml – name: Springer US
– name: Springer Nature B.V
References 9987_CR35
RJ Bauer (9987_CR17) 2021; 10
9987_CR15
9987_CR14
9987_CR16
L Nguyen (9987_CR20) 2019; 59
LK Foo (9987_CR32) 2012; 22
DR Mould (9987_CR1) 2012; 1
LB Zwep (9987_CR19) 2024; 115
EA Strömberg (9987_CR9) 2016; 43
9987_CR30
G Geenens (9987_CR21) 2020; 8
9987_CR7
M Guhl (9987_CR23) 2022; 49
9987_CR24
DJ Schuirmann (9987_CR5) 1987; 15
TT Nguyen (9987_CR12) 2012; 31
9987_CR26
9987_CR25
9987_CR28
J Seurat (9987_CR34) 2020; 29
D Menon-Andersen (9987_CR4) 2011; 90
9987_CR27
9987_CR29
F Mentre (9987_CR8) 1997; 84
9987_CR3
S Retout (9987_CR11) 2007; 26
MG Dodds (9987_CR31) 2005; 32
9987_CR6
S Retout (9987_CR18) 2003; 13
F Mentré (9987_CR10) 2013; 2
JF Marier (9987_CR2) 2022; 11
C Dumont (9987_CR13) 2018; 156
F Loingeville (9987_CR33) 2020; 30
9987_CR22
References_xml – volume: 32
  start-page: 33
  year: 2005
  ident: 9987_CR31
  publication-title: J Pharmacokinet Pharmacodyn
  doi: 10.1007/s10928-005-2102-z
– volume: 11
  start-page: 1283
  issue: 10
  year: 2022
  ident: 9987_CR2
  publication-title: CPT: Pharmacomet Syst Pharmacol
– ident: 9987_CR35
  doi: 10.1208/s12248-023-00810-9
– volume: 2
  start-page: 1
  issue: 6
  year: 2013
  ident: 9987_CR10
  publication-title: CPT: Pharmacomet Syst Pharmacol
– ident: 9987_CR7
  doi: 10.1093/oso/9780199296590.003.0004
– volume: 26
  start-page: 5162
  issue: 28
  year: 2007
  ident: 9987_CR11
  publication-title: Stat Med
  doi: 10.1002/sim.2910
– ident: 9987_CR29
  doi: 10.1002/psp4.13116
– volume: 29
  start-page: 934
  issue: 3
  year: 2020
  ident: 9987_CR34
  publication-title: Stat Methods Med Res
  doi: 10.1177/0962280219850588
– ident: 9987_CR26
– volume: 31
  start-page: 1043
  issue: 11–12
  year: 2012
  ident: 9987_CR12
  publication-title: Stat Med
  doi: 10.1002/sim.4390
– ident: 9987_CR28
  doi: 10.21203/rs.3.rs-3655068/v1
– volume: 22
  start-page: 1193
  issue: 6
  year: 2012
  ident: 9987_CR32
  publication-title: J Biopharm Stat
  doi: 10.1080/10543406.2011.580484
– volume: 156
  start-page: 217
  year: 2018
  ident: 9987_CR13
  publication-title: Comput Methods Programs Biomed
  doi: 10.1016/j.cmpb.2018.01.008
– volume: 49
  start-page: 557
  issue: 5
  year: 2022
  ident: 9987_CR23
  publication-title: J Pharmacokinet Pharmacodyn.
  doi: 10.1007/s10928-022-09821-z
– volume: 43
  start-page: 609
  year: 2016
  ident: 9987_CR9
  publication-title: J Pharmacokinet Pharmacodyn
  doi: 10.1007/s10928-016-9499-4
– volume: 115
  start-page: 795
  issue: 4
  year: 2024
  ident: 9987_CR19
  publication-title: Clin Pharmacol Ther
  doi: 10.1002/cpt.3099
– ident: 9987_CR24
– ident: 9987_CR3
– volume: 30
  start-page: 31
  issue: 1
  year: 2020
  ident: 9987_CR33
  publication-title: J Biopharm Stat
  doi: 10.1080/10543406.2019.1607367
– volume: 13
  start-page: 209
  issue: 2
  year: 2003
  ident: 9987_CR18
  publication-title: J Biopharm Stat
  doi: 10.1081/BIP-120019267
– volume: 15
  start-page: 657
  year: 1987
  ident: 9987_CR5
  publication-title: J Pharmacokinet Biopharm
  doi: 10.1007/BF01068419
– ident: 9987_CR6
  doi: 10.1002/psp4.13115
– volume: 10
  start-page: 1452
  issue: 12
  year: 2021
  ident: 9987_CR17
  publication-title: CPT: Pharmacomet Syst Pharmacol
– ident: 9987_CR16
  doi: 10.1016/S0169-2607(03)00073-7
– ident: 9987_CR30
  doi: 10.1101/2024.02.22.24303086
– volume: 90
  start-page: 471
  issue: 3
  year: 2011
  ident: 9987_CR4
  publication-title: Clin Pharmacol Ther
  doi: 10.1038/clpt.2011.149
– volume: 84
  start-page: 429
  issue: 2
  year: 1997
  ident: 9987_CR8
  publication-title: Biometrika
  doi: 10.1093/biomet/84.2.429
– volume: 59
  start-page: 1551
  issue: 11
  year: 2019
  ident: 9987_CR20
  publication-title: J Clin Pharmacol
  doi: 10.1002/jcph.1467
– volume: 1
  start-page: 1
  issue: 9
  year: 2012
  ident: 9987_CR1
  publication-title: CPT: Pharmacomet Syst Pharmacol
– ident: 9987_CR15
  doi: 10.1016/j.cmpb.2012.05.005
– ident: 9987_CR22
  doi: 10.1002/sim.10088
– ident: 9987_CR25
– ident: 9987_CR14
  doi: 10.32614/CRAN.package.PFIM
– volume: 8
  start-page: 417
  issue: 1
  year: 2020
  ident: 9987_CR21
  publication-title: Dependence Model
  doi: 10.1515/demo-2020-0022
– ident: 9987_CR27
SSID ssj0016520
Score 2.3940184
Snippet This work focuses on design of experiments for Pharmacokinetic (PK) and Pharmacodynamic (PD) studies. Non-Linear Mixed Effects Models (NLMEM) modelling allows...
SourceID proquest
pubmed
crossref
springer
SourceType Aggregation Database
Index Database
Publisher
StartPage 38
SubjectTerms Approximation
Biochemistry
Biomedical and Life Sciences
Biomedical Engineering and Bioengineering
Biomedicine
Clinical trials
Computer Simulation
Drug dosages
Humans
Methods
Models, Biological
Models, Statistical
Nonlinear Dynamics
Original Paper
Pharmaceutical industry
Pharmacodynamics
Pharmacokinetics
Pharmacology/Toxicology
Pharmacy
Simulation
Software
Statistical analysis
Uncertainty
Veterinary Medicine/Veterinary Science
Title Using Fisher Information Matrix to predict uncertainty in covariate effects and power to detect their relevance in Non-Linear Mixed Effect Models in pharmacometrics
URI https://link.springer.com/article/10.1007/s10928-025-09987-2
https://www.ncbi.nlm.nih.gov/pubmed/40659916
https://www.proquest.com/docview/3229987600
https://www.proquest.com/docview/3230216585
Volume 52
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3LatwwFBUl2XRT2vQ1bRpuoWTTEciWZEfLoeRBy4QsMjBdGdmSINDaQ-yUzP_kQ3OvbM-kJF10YS9s2RYcPc71uQ_GvtCvteCt5F6LwJU7EtwYb_FkXVA2DdZQvPP8PDtbqO9LvRyCwtrR232UJONK_SDYzVA25VRzZDU4NXDh3dVku-MoXqSzjXaQ6ZiMEQ2TnOOxHEJlnn7H39vRI475SB-N287JS_Zi4Isw6wF-xZ75eo8dXvQJp9dTuNzGT7VTOISLbSrq9Wt2Fz0CoK9vDkPoEUEBc0rNfwtdA6tr0mo6wA2udw_o1nBVQ9X8QTMamSgMLh9gawcrKqpGTzlP6gNEnQGo8Ep0JaAHz5uao4WLMwjmV7feQZ8gGajq2q-WWqyGPv6mal5V-4YtTo4vv53xoS4Dr2R61HEEXZeJcd6mIi-TUlVBSrSrRIXkQ1sjKi2dU8rmNhPSC--RVZkyIQ0yVSGRb9lO3dT-PYNMy8xYHURlpXI2mNwIF6RHHoaXVTphX0d4ilWffqPYJlomMAsEs4hgFth6f0SwGKZiW-CKRXexCxP2eXMbJxEpI7b2zQ21kch1kIzpCXvXI7_5nCLlGUn0hE3HobB9-b_78uH_mn9kz9M4LHOeqH22013f-E9Id7rygO3OTn_-OD6Io_weyJX61Q
linkProvider Springer Nature
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3LjtMwFLXQsIAN4k1hgIuEZkMtObGd1MsRYlRgWs2ilbqLnNiWRoKkmmTQ9H_4UO51khY0sGCRLGI7sXT8OM65D8be06-14K3kXovAlZsJboy3eLMuKJsGa8jfebHM5mv1ZaM3g1NYO1q7j5JkXKl_c3YzFE051RxZDU4NXHjvIhmYkSHXOj3daweZjsEY8WCSc7w2g6vM39_x53Z0i2Pe0kfjtnP2kD0Y-CKc9gA_Ynd8_ZidXPQBp3dTWB38p9opnMDFIRT17gn7GS0CoM9vDoPrEUEBCwrNfwNdA9sr0mo6wA2uNw_odnBZQ9X8wGM0MlEYTD7A1g62lFSNWjlP6gNEnQEo8Uo0JaCGy6bmeMLFGQSLyxvvoA-QDJR17VtLNbZDH79TNq-qfcrWZ59WH-d8yMvAK5nOOo6g6zIxzttU5GVSqipIiecqUSH50NaISkvnlLK5zYT0wntkVaZMSINMVUjkM3ZUN7V_wSDTMjNWB1FZqZwNJjfCBemRh-FjlU7YhxGeYtuH3ygOgZYJzALBLCKYBdY-HhEshqnYFrhiUSl2YcLe7YtxEpEyYmvfXFMdiVwHyZiesOc98vvPKVKekURP2HQcCoeX_7svL_-v-lt2b75anBfnn5dfX7H7aRyiOU_UMTvqrq79a6Q-XfkmjvRf4lf8NA
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Na9wwEBUlhdJL6Xe3SdsplFy6IrIl2dExtF3Sj132kIW9GdmSIJDaJuuU7P_JD-2M7N1NSXvowT7Ysi2YkfTkN_OGsQ_0ay14K7nXInDljgU3xls8WReUTYM1lO88nWWnC_VtqZe3svhjtPuGkuxzGkilqe6OWheObiW-GVJWTjVHhIPDBCfh-zgdJ-TXi_RkyyNkOgoz4iYl53gsh7SZv7_jz6XpDt68w5XGJWjymD0asCOc9MZ-wu75-ik7nPfi0-sxnO1yqVZjOIT5TpZ6_YzdxOgA6Gudw5CGRGaBKcn0X0PXQHtJvE0HuNj1oQLdGs5rqJpfuKVGVApD-AfY2kFLBdboKeeJiYDIOQAVYYlhBfTgrKk57nZxNMH0_No76MWSgSqwXayoRTv08SdV9qpWz9li8uXs0ykfajTwSqbHHUcH0GVinLepyMukVFWQEvdYokIgoq0RlZbOKWVzmwnphfeIsEyZEB-ZqpDIF2yvbmr_ikGmZWasDqKyUjkbTG6EC9IjJsPLKh2xjxvzFG0vxVHsRJfJmAUas4jGLLD1wcaCxTAsVwXOXnQXuzBi77e3cUARS2Jr31xRG4m4B4GZHrGXveW3n1PEQiOgHrHxxhV2L_93X17_X_N37MH886T48XX2fZ89TKOH5jxRB2yvu7zybxAFdeXb6Oi_AS8cAH8
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Using+Fisher+Information+Matrix+to+predict+uncertainty+in+covariate+effects+and+power+to+detect+their+relevance+in+Non-Linear+Mixed+Effect+Models+in+pharmacometrics&rft.jtitle=Journal+of+pharmacokinetics+and+pharmacodynamics&rft.au=Fayette%2C+Lucie&rft.au=Brendel%2C+Karl&rft.au=Mentr%C3%A9%2C+France&rft.date=2025-07-14&rft.issn=1567-567X&rft.eissn=1573-8744&rft.volume=52&rft.issue=4&rft_id=info:doi/10.1007%2Fs10928-025-09987-2&rft.externalDBID=n%2Fa&rft.externalDocID=10_1007_s10928_025_09987_2
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1567-567X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1567-567X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1567-567X&client=summon